Sodium-glucose cotransporter-2 inhibitor therapy and risk of mortality and morbidity following hospitalization for pneumonia in type 2 diabetes mellitus: An international propensity score-matched cohort study.
Diabetes patients taking SGLT2 inhibitors had lower risks of death and complications after pneumonia hospitalization, contrary to earlier safety concerns.
This PubMed record examines Sodium-glucose cotransporter-2 inhibitor therapy and risk of mortality and morbidity following hospitalization for pneumonia in type 2 diabetes mellitus: An international propensity score-matched cohort study. It reports CONCLUSION: Patients with T2DM who used SGLT2 inhibitors had significantly lower risks of mortality and morbidity following hospitalization for pneumonia, including a notable reduction in DKA, contrary to prior concerns.
What the study was
- Study design
- Randomized controlled trial
- Population
- Human participants
- Category
- Public Health
- Maturity
- Validated
- Journal
- Sage open chronic disease
Why it surfaced
Randomized controlled trial; conservative rapid-triage score based on PubMed title, publication type, and abstract.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.